Home Stock

Stock Research: Daewoong Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Daewoong Pharmaceutical

KSC:069620 KR7069620003
76
  • Value
    74
  • Growth
    35
  • Safety
    Safety
    39
  • Combined
    48
  • Sentiment
    98
  • 360° View
    360° View
    76
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Daewoong Pharma manufactures and distributes pharmaceuticals. It operates in the pharmaceutical industry, producing drugs for various treatments. The company distributes its products domestically and internationally. In the last fiscal year, the company had a market cap of $1,374 million, profits of $497 million, and revenue of $963 million. The number of employees is not available.

more

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Daewoong Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Daewoong Pharmaceutical. The consolidated Value Rank has an attractive rank of 74, which means that the share price of Daewoong Pharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 74% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 98, which means that professional investors are more optimistic about the stock than for 98% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 35, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 39, meaning the company has a riskier financing structure than 61 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Capital Growth
Weakest Rank Sentiment
Country South Korea
Industry Pharmaceuticals
Size Medium
Website daewoong.co.kr
Index
KOSPI
Daewoong Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
74 34 40 27
Growth
35 98 43 23
Safety
Safety
39 13 14 8
Sentiment
98 94 67 20
360° View
360° View
76 30 23 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
64 88 93 5
Opinions Change
50 50 50 4
Pro Holdings
n/a 62 38 63
Market Pulse
95 84 61 86
Sentiment
98 94 67 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
74 34 40 27
Growth
35 98 43 23
Safety Safety
39 13 14 8
Combined
48 1 12 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
64 65 74 52
Price vs. Earnings (P/E)
59 44 53 23
Price vs. Book (P/B)
48 24 31 24
Dividend Yield
71 27 26 21
Value
74 34 40 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
26 59 52 47
Profit Growth
71 100 87 40
Capital Growth
8 87 40 27
Stock Returns
55 80 13 51
Growth
35 98 43 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
23 30 13 14
Refinancing
30 8 5 19
Liquidity
80 40 41 14
Safety Safety
39 13 14 8

Similar Stocks

Discover high‑ranked alternatives to Daewoong Pharmaceutical and broaden your portfolio horizons.

NSK

TYO:6471
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Brother Industries

TYO:6448
Country: Japan
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews